Cargando…

COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review

INTRODUCTION: Immune checkpoint inhibitors (ICIs) can cause inflammatory and immune-related adverse events (irAEs) that might worsen the course of COVID-19. We conducted a systematic review (PROSPERO ID: CRD42022307545) to evaluate the clinical course and complications of COVID-19 in patients with c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiz, Juan I., Lopez-Olivo, Maria A., Geng, Yimin, Suarez-Almazor, Maria E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Innovative Healthcare Institute 2023
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195019/ https://www.ncbi.nlm.nih.gov/pubmed/37214207 http://dx.doi.org/10.36401/JIPO-22-24

Ejemplares similares

COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
por: Ruiz, Juan Ignacio, et al.
Publicado: (2023)

Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
por: Lopez-Olivo, Maria A., et al.
Publicado: (2022)

Quality and content evaluation of websites with information about immune checkpoint inhibitors: An environmental scan
por: Ruiz, Juan Ignacio, et al.
Publicado: (2022)

Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
por: Lopez-Olivo, Maria A., et al.
Publicado: (2023)

The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
por: Bruera, Sebastian, et al.
Publicado: (2022)

Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study
por: Lopez-Olivo, Maria A., et al.
Publicado: (2023)

Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors
por: Riveiro-Barciela, Mar, et al.
Publicado: (2023)

Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Multidisciplinary approach to treatment with immune checkpoint inhibitors in patients with HIV, tuberculosis, or underlying autoimmune diseases
por: Aguilar-Company, Juan, et al.
Publicado: (2022)

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
por: Abdel-Wahab, Noha, et al.
Publicado: (2016)

COVID-19 Outcomes in Stage IV Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Guo, Mengni, et al.
Publicado: (2022)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
por: Safa, Houssein, et al.
Publicado: (2019)

Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab
por: Qureshi, Sehrish, et al.
Publicado: (2023)

Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
por: Kim, Sang T., et al.
Publicado: (2019)

Systematic review of the methodological quality of controlled trials evaluating Chinese herbal medicine in patients with rheumatoid arthritis
por: Pan, Xin, et al.
Publicado: (2017)

Knowledge, beliefs, and concerns about bone health from a systematic review and metasynthesis of qualitative studies
por: des Bordes, Jude, et al.
Publicado: (2020)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer
por: Suarez-Almazor, Maria E., et al.
Publicado: (2022)

Diagnostic and therapeutic approach to pulmonary infiltrates in cancer patients receiving immune checkpoint inhibitors
por: Fernández-Ruiz, Mario
Publicado: (2022)

Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department
por: Castillo, Richmond M., et al.
Publicado: (2021)

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
por: Mamlouk, Omar, et al.
Publicado: (2019)

QUALITY OF LIFE IN OLDER ADULTS RECEIVING IMMUNE CHECKPOINT INHIBITOR THERAPY
por: Hoogland, Aasha I, et al.
Publicado: (2019)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
por: Zhang, Liyan, et al.
Publicado: (2021)

Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors
por: Moshirfar, Majid, et al.
Publicado: (2022)

Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
por: Gilbert, Danielle, et al.
Publicado: (2023)

Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma
por: Wang, Qiyu, et al.
Publicado: (2022)

Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review
por: Barron, Carly C, et al.
Publicado: (2023)

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
por: Awadalla, Magid, et al.
Publicado: (2019)

Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors
por: Panneerselvam, Kavea, et al.
Publicado: (2022)

Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
por: Vasavada, Shaleen, et al.
Publicado: (2022)

Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis
por: Qian, Xiaoyan, et al.
Publicado: (2023)

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis
por: Karpes Matusevich, Aliza R, et al.
Publicado: (2021)

Psychosocial Determinants of Total Knee Arthroplasty Outcomes Two Years After Surgery
por: Lopez‐Olivo, Maria A., et al.
Publicado: (2020)

Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
por: Strobel, Sophia B., et al.
Publicado: (2021)

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Pietrantonio, Filippo, et al.
Publicado: (2021)

38351 Immune-related adverse events in cancer patients receiving immune checkpoint inhibitors
por: Lucas, Margaret Byrnethew, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pjrnp3ppipsufkhqj09ekoaqom